Zynerba Pharmaceuticals — Investor Presentation (January 2020)
39 slides from Zynerba Pharmaceuticals's investor presentation, Jan 13, 2020
Slide 1: Corporate Overview January 2020
Corporate Overview January 2020
Slide 2: Forward-Looking Statements
Forward - Looking Statements 2 © 20 20 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE
Slide 3: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline focused on high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel ™(CBD gel) • Four clinical shots on goal: FXS, DEE, ASD, 22q • Approaching enrollment target
Slide 4: Deep Clinical Pipeline
Deep Clinical Pipeline 4 *Orphan Drug Designation Zygel Cannabidiol Gel Expected Milestones Topline pivotal data in 2Q2020 Topline Phase 2 data in 2Q2020 Topline Phase 2 data in 2Q2020 Meet with FDA in 1H2020 to discuss clinical path forward
Slide 5: Zygel (ZYN002) Cannabidiol Gel
Neuropsych Indications Differentiated F ormulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 5 Unique MOA First & only patent - protected, permeation - enhanced, pharmaceutically - produced CBD gel Transdermal CBD modulates multiple recep
Slide 6: Fragile X Syndrome (FXS)
Fragile X Syndrome (FXS) 6
Slide 7: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 7 • Rare genetic developmental disability • L eading known cause of both inherited intellectual disability and autism spectrum disorder • Symptoms linked to deficiencies in the endocannabinoid (EC) system • System of neurotransmitters regulating emotional responses,
Slide 8: FAB-C Open Label Phase 2 Trial Design
Day 1 to Week 6 Week 7 to 12 Up to 24 months FAB - C Open Label Phase 2 Trial Design 8 Treatment of F ragile X Syndrome A nxiety and B ehavioral C hallenges with CBD Titration Maintenance Screening Open label extension D osing initiated at 50 mg Zygel daily; may be titrated up to 250 mg Zygel daily
Slide 9: Data From Three Month FAB-C Phase 2 Trial
Data From Three Month FAB - C Phase 2 Trial 9 0 10 20 30 40 50 60 70 Social Avoidance Irritability Socially Unresponsive / Lethargic Inappropriate Speech Stereotypy Hyperactivity Month 3 (n=18) Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 32
Slide 10: Third Party Data Suggest Placebo Rate
Third Party Data* Suggest PBO Rate of 10 to 18 Percent 10 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 50 Zygel 0 10 20 30 40 50 60 Zygel 0 10 20 30 40 Zygel Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phra
Slide 11: Sustained Improvements in FXS Behavioral Symptoms Through 12 Months
Three Month FAB - C Data vs. 12 Months of Treatment 11 0 10 20 30 40 50 60 70 80 90 Social Avoidance Irritability Socially Unresponsive Hyperactivity Stereotypy Inappropriate Speech Month 3 (n=12) Month 12 (n=9) 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P ≤ 0.05 Mean % Improvement from Baseline 77.2* 59.
Slide 12: Zygel Safety Summary Through 12 Months
FAB - C Open Label Phase 2 12 • Well tolerated, consistent with previously reported data; no SAEs • No clinically meaningful trends in vital signs, ECG, or clinical safety labs including LFTs; no THC detected in plasma • Discontinuations • Two siblings discontinued in Period 1 • One for worsening of
Slide 13: CONNECT-FX: A Pivotal Trial In FXS
CONNECT - FX: A Pivotal Trial In FXS 13 C linical study O f Ca NN abidiol (CBD) in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel 250 mg daily 500 mg daily (weight - based dose) Placebo Mirrors Zygel administration Patients randomized (1:1) to receive either Zygel or placebo Tre
Slide 14: CONNECT-FX: A Pivotal Trial In FXS Endpoints
CONNECT - FX: A Pivotal Trial In FXS 14 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/L
Slide 15: CONNECT-FX Enrollment Status and Demographics
CONNECT - FX Enrollment Status and Demographics 15 Patients n* Randomized (target =204) 178 Screened but not yet randomized 15 Completed 14 - week Tx period 141 Percent of completed patients enrolling in CONNECT - FX OLE 96% *As of January 10, 2020 Screening Expected to Complete by End of January 20
Slide 16: Baseline Behavior Severity: CONNECT-FX vs Ph2 FAB-C
Baseline Behavior Severity: CONNECT - FX vs Ph2 FAB - C 16 Prospective inclusion criteria expected to provide a more severely impacted population which we believe should enhance ability to demonstrate a strong signal of activity and minimize response variability Note : Higher baseline scores denote
Slide 17: CONNECT-FX Regulatory Path
CONNECT - FX 17 • W ith positive results in pivotal trial, Zynerba intends to request a meeting with the FDA to : • Determine acceptability of data as basis for NDA filing by YE 2020 • Seek advice on marketing authorization preparation • Potential approval by mid - year 2021 • Zynerba believes the i
Slide 18: Improvements in Behavior May Provide Read-Through to Other Zygel Studies
18 • Presented data at SSBP* showing constellation of shared socio - behavioral symptoms in ASD, FXS, and 22q11.2DS • These include anxiety leading to: • Isolation and social avoidant behaviors • Irritability • Attention deficits • Poor communication Improvements in Behavior May Provide a Read - Thr
Slide 19: Autism Spectrum Disorder (ASD) in pediatric patients
19 Autism Spectrum Disorder (ASD) in pediatric patients
Slide 20: ASD in Pediatrics Overview
ASD in Pediatrics Overview 20 • Near - rare disorder affecting ~ 1MM pediatric and adolescent pts • DSM - 5 diagnosis • Includes Autistic disorder, Asperger’s syndrome, and Pervasive Development Disorder - not otherwise specified (PDD - NOS) • Symptoms include • Anxiety • Restricted, repetitive patt
Slide 21: Developing Zygel in ASD
Developing Zygel in ASD 21 • Newer studies suggest ASD is linked to disruption in the EC system • Altered anandamide signaling may contribute to ASD - related social and communication impairments • EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergi
Slide 22: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 22 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder Target: 36 patients Four through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg
Slide 23: BRIGHT Trial Patient Demographics
BRIGHT Trial Patient Demographics 23 36 patients enrolled in the BRIGHT trial: • 94% of patients have moderate to severe symptoms of ASD at baseline as measured by the Autism Diagnostic Observation Schedule (ADOS - 2) • Mean baseline ABC - C Irritability subscale: 30.0 • 33 (92%) are male • Mean age
Slide 24: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome ( 22q) 24
Slide 25: 22q Overview
22q Overview 25 • Most common contiguous gene deletion syndrome • Rare disorder: ~81K patients in US • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities
Slide 26: 22q Patient Management
22q Patient Management 26 • Two primary stages of 22q patient management: • During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery • Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety an
Slide 27: Developing Zygel in 22q
Developing Zygel in 22q 27 • CBD may treat neuropsychiatric symptoms in 22q due to activity as: • Modulator of endocannabinoid system • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors • Early control of anxiety may delay the development of psychosis • Phase 2 study underway in pedi
Slide 28: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 28 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily Follow up assessments Week 16 / 17 E fficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community ( ABC - C) •
Slide 29: DEE Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 29
Slide 30: DEE Patients are Medically Fragile
DEE Patients are Medically Fragile 30 • G roup of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral
Slide 31: BELIEVE Phase 2 Trial in DEE
BELIEVE 1 Phase 2 Trial in DEE 31 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Ti
Slide 32: BELIEVE 1: Clinically Meaningful Seizure Reductions from Baseline
32 BELIEVE 1: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE 0 10 20 30 40 50 60 70 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Median Percent Reduction from Baseline, FIAS and CS N=33 N=33 N=33 N=32 N=32 N=29 16 44 44 47 58 51 0 10 20 30 40 50 60
Slide 33: BELIEVE 1 Safety: Well Tolerated in this Six Month Trial
33 • All events in six month period, whether unrelated or related to study, drug are reported as adverse events (AEs) (e.g.: influenza, runny nose, ingrown toenail, scrapes, etc.) • AEs common in this medically fragile population, and expected in a six - month trial • As a result, most patients expe
Slide 34: BELIEVE 1: Qualitative Assessments of Behavioral and Cognitive Improvements
34 • Parents and caregivers provided qualitative assessment on their child’s overall experiences with Zygel • Improvements were seen in seizure intensity and duration , and socio - behavioral and cognitive impairments • Improvements in >25% of children: • 58 % reported improved vitality (e.g. alertn
Slide 35: Compelling Results Suggest a Pathway to Pivotal Trials
35 • Efficacy results: • Clinically meaningful reductions in seizures beginning in month two and sustained through six months • Suggest improvements on important behavioral symptoms • Safety results: • Zygel was well tolerated • Consistent with previously reported Zygel studies • May compare favorab
Slide 36: Planned Approach to FDA
36 Syndromes and encephalopathies Dravet LGS West Early myoclonioc epilepsy Hypoxic - ischemic e nceph . S eizure type Focal Impaired Awareness Bilateral Tonic Clonic Generalized Tonic Clonic Focal aware Absence Convulsive Other Seizure types Consciousness impairing seizures Doose Ohtahara Landau -
Slide 37: Financial Strength
Financial Strength 37 • Clean balance sheet • No debt, 23.2M shares outstanding (as of November 1, 2019) • Cash and cash equivalent position of $77.5M as of September 30, 2019 • Cash expected to be sufficient to fund operations and capital requirements into the second half of 2021 • Beyond the expec
Slide 38: Expected Clinical Milestones in 2020
Expected Clinical Milestones in 2020 38 FXS DEE Report pivotal CONNECT - FX topline results ASD 22q 1Q 2Q Report Ph. 2 BRIGHT topline results Report Ph. 2 INSPIRE topline results 3Q 4Q Meet with FDA to discuss DEE pivotal program NDA submission
Slide 39: Corporate Overview January 2020
Corporate Overview January 2020
Zynerba Pharmaceuticals — Investor Presentation (January 2020) on 6ix